Abstract: CD81 belongs to a family of cell-surface proteins (tetraspanins) known to be up-regulated in rheumatoid arthritis (RA) synoviocytes. Recently, we showed that small interfering RNA targeting CD81 (CD81 siRNA) has a therapeutic effect on RA. We also showed that CD81 siRNA decreased the expression of TNF-in SW982 cells, suggesting that TNF-stimulates the expression of synoviolin via CD81. Here, we show that a monoclonal antibody (MAb) against CD81, which was raised by immunization with recombinant CD81, decreased the proliferation of rat C6 glioma cells, showing that this antibody is functionally active and probably inhibits cell proliferation through the inhibition of CD81 function on the cell surface.
Introduction
CD81 belongs to a family of cell-surface proteins known as the tetraspanins. It influences adhesion, morphology, activation, proliferation, and differentiation of B and T cells 1, 2) . Our previous gene profiling study of rheumatoid arthritis (RA) synoviocytes using genome-wide DNA chips found that CD81 is involved with proteins up-regulated in RA synoviocytes in vitro 3) . We also found that stimulation with CD81 induces the upregulation of synoviolin in SW982 cells 4) . Recent studies have demonstrated that synoviolin functions as a rheumatoid regulator for the overgrowth of synovial tissues in patients with RA 5, 6) . Mice with overexpression of synoviolin develop spontaneous arthropathy accompanied by synovial dysplasia 5) . Conversely, synoviolin/hrd1 +/-mice are resistant to collagen-induced arthritis (CIA) via enhanced apoptosis of synovial cells 6) . Thus, synoviolin expression appears to be highly associated with the development of RA through apoptosis 5-7) . We showed that CD81 siRNA decreases the TNF--induced expression of synoviolin in SW982 cells, suggesting that TNF-stimulates the expression of synoviolin via CD81 8) . Then we analyzed whether abnormal proliferation of RA synoviocytes, which may be caused by the overexpression of synoviolin, is ameliorated by the inhibition of CD81. We recently found a therapeutic effect of small interfering RNA (siRNA) targeting CD81 by an in vivo electroporation method in CIA rats 9) . For therapeutic use, the development of functional anti-CD81 antibodies is necessary. In the present study, we developed an effective anti-CD81 monoclonal antibody that inhibited cell proliferation.
Materials and Methods

Cell culture
Rat C6 glioma cells were maintained in Dulbecco's modified Eagle's medium (DMEM) with low glucose (Invitrogen, Carlsbad, CA) supplemented with 10 % fetal calf serum in a humidified atmosphere containing 5 % CO 2 at 37 °C. Mouse myeloma cells and hybridoma cells were maintained in RPMI1640 medium supplemented with 10% fetal calf serum in a humidified atmosphere containing 5 % CO 2 at 37 °C.
Establishment of hybridoma cell lines
Animal experiments were conducted according to the Guidelines regarding Animal Research of the Shujitsu University School of Pharmacy. Balb/c mice were immunized with recombinant CD81 antigen to stimulate antibody production. Spleen cells from immunized mice were isolated, and 1×10 8 cells
were fused with 1×10 7 myeloma cells by using polyethylene glycol (PEG). Fused cells were distributed into 96-well plates, and hybridoma cells were selected by using HAT medium. ELISA was used to determine hybridoma wells that showed the highest titer to the antigen. Briefly, a buffered solution of the antigen is added to each well of 96-well plates, and a solution of bovine serum albumin is added to the wells. Then the monoclonal antibody is added to the antigen coated wells. Next, a secondary antibody is added, which will bind the primary antibody. This secondary antibody has an enzyme attached to it, and a substrate for this enzyme is then added. The color change shows the amount of secondary antibody bound to primary antibody. A spectrometer is used to give quantitative values for color strength. Hybridoma cells in several wells that showed the highest titer were subcloned in other wells, and several hybridoma clones that showed the highest titers were selected by ELISA.
Production of monoclonal antibody
A volume of 0.5 ml of 2,6,10,14-tetramethylpentadecane (pristane) was injected into Balb/c mice by intraperitoneal administration one week before the hyboridoma injection. Hybridoma cells were cultured in RPMI1640 medium supplemented with 10% fetal calf serum, and 10 6 cells were injected into each mouse by intraperitoneal administration. After 10-14 days, ascites were collected from these mice and stored at -20 °C. Monoclonal antibody (IgG) in these ascites was purified by using Protein G Sepharose 4 (GE Healthcare UK Ltd., UK).
Monoclonal antibody (IgM) in these ascites was purified by using HiTrap IgM Purification HP (GE Healthcare UK Ltd., UK).
Cell proliferation assay
Five thousand cells in 100 l medium were inoculated into each well of a 96-well plate. Fifty microliters of 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) (Roche Applied Science, Penzburg, Germany) solution was added to each well, followed by incubation for 2 h. During this period, XTT was converted into a colored, soluble formazan salt by the metabolic activity of viable cells. The amount of formazan was quantified by an ELISA plate reader at 450 nm.
Results
Establishment of hybridoma cell lines
Hybridoma cells that showed the highest titer in 96-well plates were subcloned in other wells, and 10 hybridoma clones that showed the highest titer were selected by ELISA. Their growth rates are shown in Table 1 . We obtained five IgM producing clones and five IgG1 producing clones. Clone 1-1 E10-1 F8 showed the highest titer. 10 6 cells of each clone were injected into each mouse by intraperitoneal administration. After 10-14 days, ascites were collected from these mice. The volumes of the ascites from four clones are shown in Table 2 . As shown in the table, 9.7-13.4 ml of ascites were obtaind from each mouse injected 10 6 cells. .
Production of monoclonal antibody
Among the 10 hybridoma clones, several clones that produced IgG1 monoclonal antibodies were selected, and the IgG1 monoclonal antibody was purified from ascites fluid by using (Fig. 1) . In SDS-PAGE in non-reducing conditions, an IgG1 monoclonal antibody of about 150 kDa was clearly shown in an eluted fraction. Also IgM monoclonal antibody was purified by using HiTrap IgM. The eluted fraction was concentrated, and the titer of the monoclonal antibodies were analyzed by ELISA. As shown Fig. 2 , two IgM monoclonal antibodies showed a high titer to the antigen compared with the titer of antiserum.
Cell proliferation assay
To test whether this anti-CD81 IgG1 monoclonal antibody has binding affinity to CD81 on the cell surface and can inhibit cell proliferation, XTT assays were performed with rat C6 glioma cells. When cells were inoculated into 96-well plates, IgG monoclonal antibody was added to each well simultaneously. As shown that this monoclonal antibody has binding ability to both human and rat CD81, and that this monoclonal antibody has some inhibitory functions against CD81.
Discussion
In this study, we established hybridoma clones that produced anti-CD81 monoclonal antibodies, and succeeded in the production and purification of an IgG1 monoclonal antibody. We also showed that this antibody inhibited the proliferation of rat glioma cells. There have been previous studies concerning the establishment of monoclonal antibodies against CD81. CD81 was originally found to be a target of monoclonal antibodies (TAPA-1) that induced a reversible antiproliferative effect on a human lymphoma cell line 10, 11) . In one Epstein-Barr virus-positive (EBV)-B lymphoblastoid cell line, the antiproliferative antibody-1, which recognizes TAPA-1/CD81, up-regulates the release of tumor necrosis factor-alpha (TNF-) 12) . Some anti-CD81 monoclonal antibodies block the binding of hepatitis C virus E2 to CD81 13) .
There is also one report showing that anti-CD81 antibodies inhibit the proliferation of rat astrocytes 14) . Given this evidence, it appears that CD81 is not only related to RA through the induction of TNFand overexpression of synoviolin via TNF-, which induces abnormal growth of synoviocytes, but is related to the promotion of cell proliferation of normal cells and tumor cells by other mechanisms. It has been reported that TNF-and IL-1 induce synoviolin expression through activation of Erk1/2-ETS1 signalregulated kinase in synovial fibroblasts 15) . Similar mechanisms may be at work in CD81-dependent proliferation of normal and tumor cells. We have already shown that CD81 knockdown by CD81 siRNA decreases synoviolin expression and suppresses arthritis in a CIA rat model 9) . In this study, we have established an
IgG1 monoclonal antibody that inhibited the proliferation of the rat glioma cell line C6. In the same way, CD81 might become a clinical target for the suppression of tumor cell progression and/ or metastasis, and anti-CD81 monoclonal antibodies could become effective therapeutic agents with CD81-expressing tumor cells as their targets.
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